Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Steroid refractory CD4+ T Cells in patients with sight-threatening uveitis

Lee, Richard W. J., Schewitz, Lauren P., Nicholson, Lindsay B., Dayan, Colin Mark ORCID: and Dick, Andrew D. 2009. Steroid refractory CD4+ T Cells in patients with sight-threatening uveitis. Investigative Ophthalmology and Visual Science 50 (9) , pp. 4273-4278. 10.1167/iovs.08-3152

[thumbnail of Lee 2009.pdf]
PDF - Published Version
Download (628kB) | Preview


purpose. A discrete subpopulation of steroid refractory (SR) CD4+ T cells has recently been identified in patients with SR ulcerative colitis (UC). The purpose of this study was to test whether this subpopulation is also present in patients with clinically defined SR uveitis. As interleukin (IL)-2 experimentally mediates the SR phenotype, the combined effects of dexamethasone (Dex) and a range of IL-2 targeting immunosuppressive agents were also investigated. methods. Peripheral blood mononuclear cells (PBMCs) from 27 patients with uveitis and 4 normal volunteers were cultured for 5 days with CD3-CD28 beads. In vitro steroid refractivity or responsiveness was determined by the presence or absence of a subpopulation of SR CD4+ cells (as previously reported for UC) that continued to proliferate or not in the presence of Dex. The patients were concurrently classified by a masked investigator as having clinically SR (threshold for disease reactivation, ≥10 mg prednisone daily) or steroid sensitive (SS) disease. results. There was 78% (21/27) agreement between the in vitro and clinical classifications of SR and SS disease (κ coefficient = 0.56, P = 0.002). This finding corresponds to a positive predictive value of 90% and a negative predictive value of 71%. In normal volunteers, basiliximab, daclizumab, and AG490 achieved an equivalent augmentation of CD4+ cell suppression in combination with Dex. conclusions. As in UC, patients with SR uveitis have a subpopulation of SR CD4+ cells that are a potential target for intervention with anti–IL-2 therapies, including inhibitors of JAK/STAT signaling. The identification of SR T cells also has potential clinical application as a biomarker for SR disease.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Systems Immunity Research Institute (SIURI)
Subjects: R Medicine > R Medicine (General)
R Medicine > RE Ophthalmology
R Medicine > RM Therapeutics. Pharmacology
Additional Information: Confirmation received by publisher on 21 February 2014 that publisher's pdf can be self-archived 6 months after publication.
Publisher: Association for Research in Vision and Ophthalmology
ISSN: 0146-0404
Date of First Compliant Deposit: 30 March 2016
Last Modified: 09 May 2023 12:00

Citation Data

Cited 26 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item


Downloads per month over past year

View more statistics